Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Energy Fuels Aktie: Achtung, Aufholpotenzial! (Aktiencheck) +++ ENERGY FUELS Aktie -3,11%

PLIANT THERAPEUTICS Aktie

 >Aktienkurs 
1.07 EUR    +0.0%    (Tradegate)
Ask: 1.07 EUR / 4630 Stück
Bid: 1.06 EUR / 4717 Stück
Tagesumsatz: 119 Stück
Realtime Kurs von 8 bis 22 Uhr!
Aktie über LYNX handeln
>Performance
1 Woche: -2,7%
1 Monat: -26,7%
3 Monate: -12,3%
6 Monate: -91,8%
1 Jahr: -89,1%
laufendes Jahr: -91,7%
>PLIANT THERAPEUTICS Aktie
Name:  PLIANT THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US7291391057 / A2P4YV
Symbol/ Ticker:  9PT (Frankfurt) / PLRX (NASDAQ)
Kürzel:  FRA:9PT, ETR:9PT, 9PT:GR, NASDAQ:PLRX
Index:  -
Webseite:  https://pliantrx.com/
Marktkapitalisierung:  78.37 Mio. EUR
Umsatz:  -
EBITDA:  -
Gewinn je Aktie:  -
Schulden:  -
Liquide Mittel:  -
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  37.42 / -
KUV/ KBV/ PEG:  2650 / 0.35 / -
Gewinnm./ Eigenkapitalr.:  - / -47.52%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  PLIANT THERAPEUTICS, PLIANT THERAPEUTIC
Letzte Datenerhebung:  05.07.25
>Eigentümer
Aktien: -
f.h. Aktien: -
Insider Eigner: 2.91%
Instit. Eigner: 111.7%
>Peer Group

 
27.06.25 - 22:09
 Pliant Therapeutics Provides Update on BEACON-IPF (GlobeNewswire EN)
 
Bexotegrast development in IPF discontinued...
21.05.25 - 22:06
 Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference (GlobeNewswire EN)
 
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025....
09.05.25 - 00:03
 Pliant Therapeutics GAAP EPS of -$0.92 misses by $0.18 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.05.25 - 16:33
 Pliant Therapeutics to trim about 45% of workforce (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.05.25 - 22:09
 Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations (GlobeNewswire EN)
 
-  Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials...
07.04.25 - 22:09
 Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference (GlobeNewswire EN)
 
SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California from May 16-21, 2025....
28.03.25 - 15:00
 INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Pliant Therapeutics stock or options and would like to......
13.03.25 - 16:06
 SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics (PR Newswire)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Pliant Therapeutics To Contact Him Directly To Discuss Their Options If you suffered significant losses in Pliant Therapeutics stock or options and would like to......
13.03.25 - 12:24
 Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement (GlobeNewswire EN)
 
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests....
05.03.25 - 01:48
 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc- PLRX (PR Newswire)
 
NEW YORK, March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
03.03.25 - 23:06
 Pliant Therapeutics GAAP EPS of -$0.82 beats by $0.17 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.03.25 - 19:12
 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX (PR Newswire)
 
NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
03.03.25 - 15:30
 Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire EN)
 
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial's independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, Pliant has discontinued the BEACON-IPF Phase 2b trial evaluating bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). While an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups led to the discontinuation of the trial, early evidence of efficacy on the forced vital capacity (FVC) endpoint was also observed....
25.02.25 - 23:03
 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. - PLRX (PR Newswire)
 
NEW YORK, Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......
10.02.25 - 14:42
 Pliant Therapeutics Pauses Lead Product Mid-Stage Trial In Patients With Stiff Lung Tissues (Benzinga)
 
Pliant Therapeutics halted new enrollment in its BEACON-IPF trial after a safety board review. A separate study showed bexotegrast reduced lung collagen. read more...
07.02.25 - 23:00
 Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis (GlobeNewswire EN)
 
Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed...
23.01.25 - 02:01
 Insiderhandel: Chief Financial Officer verkauft Aktien von Pliant Therapeutics Inc im Wert von 225680 USD (Insiderkauf)
 
Cummings, Keith Lamont - Vorstand - Tag der Transaktion: 2025-01-17...
23.01.25 - 02:01
 Insiderhandel: General Counsel & Corp. Secy verkauft Aktien von Pliant Therapeutics Inc im Wert von 148639 USD (Insiderkauf)
 
Ouimette, Mike - Vorstand - Tag der Transaktion: 2025-01-17...
23.01.25 - 02:01
 Insiderhandel: Chief Business Officer verkauft Aktien von Pliant Therapeutics Inc im Wert von 178501 USD (Insiderkauf)
 
Hull, Hans - Vorstand - Tag der Transaktion: 2025-01-17...
23.01.25 - 02:01
 Insiderhandel: General Counsel & Corp. Secy verkauft Aktien von Pliant Therapeutics Inc im Wert von 112462 USD (Insiderkauf)
 
Ouimette, Mike - Vorstand - Tag der Transaktion: 2025-01-22...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Kein Kaiser kann, was unser ist, verschenken. - Friedrich Johann Christoph Schiller
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!